Search

Your search keyword '"Augustine, Alison D"' showing total 5 results
Start Over Author "Augustine, Alison D" Topic humans
5 results on '"Augustine, Alison D"'

1. IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition

Author

Ozonoff, Al, Ehrlich, Lauren IR, Melamed, Esther, Sesma, Ana Fernandez, Simon, Viviana, Pulendran, Bali, Nadeau, Kari C, Davis, Mark M, McCoey, Grace A, Sekaly, Rafick, Baden, Lindsey R, Levy, Ofer, Schaenman, Joanna, Reed, Elaine F, Shaw, Albert C, Hafler, David A, Montgomery, Ruth R, Kleinstein, Steven H, Becker, Patrice M, Augustine, Alison D, Calfee, Carolyn S, Erle, David J, DeBakey, Michael E, Corry, David B, Kheradmand, Farrah, Atkinson, Mark A, Brakenridge, Scott C, Higuita, Nelson I Agudelo, Metcalf, Jordan P, Hough, Catherine L, Messer, William B, Kraft, Monica, Bime, Chris, Peters, Bjoern, Milliren, Carly E, Syphurs, Caitlin, McEnaney, Kerry, Barton, Brenda, Lentucci, Claudia, Saluvan, Mehmet, Chang, Ana C, Hoch, Annmarie, Albert, Marisa, Shaheen, Tanzia, Kho, Alvin T, Liu, Shanshan, Thomas, Sanya, Chen, Jing, Murphy, Maimouna D, Cooney, Mitchell, Hayati, Arash Nemati, Bryant, Robert, Abraham, James, Jayavelu, Naresh Doni, Presnell, Scott, Jancsyk, Tomasz, Maguire, Cole, Qi, Jingjing, Lee, Brian, Fourati, Slim, Esserman, Denise A, Guan, Leying, Gygi, Jeremy, Pawar, Shrikant, Brito, Anderson, Fragiadakis, Gabriela K, Patel, Ravi, Overton, James A, Vita, Randi, Westendorf, Kerstin, Shannon, Casey P, Tebbutt, Scott J, Thyagarajan, Rama V, Rousseau, Justin F, Wylie, Dennis, Triplett, Todd A, Kojic, Erna, Chinthrajah, Sharon, Ahuja, Neera, Rogers, Angela J, Artandi, Maja, Geng, Linda, Yendewa, George, Powell, Debra L, Kim, James N, Simmons, Brent, Goonewardene, I Michael, Smith, Cecilia M, Martens, Mark, Sherman, Amy C, Walsh, Stephen R, Issa, Nicolas C, Salehi-Rad, Ramin, Dela Cruz, Charles, Farhadian, Shelli, Iwasaki, Akiko, Ko, Albert I, Anderson, Evan J, Mehta, Aneesh K, and Sevransky, Jonathan E

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Immunology, Coronaviruses, Infectious Diseases, Emerging Infectious Diseases, Lung, Inflammatory and immune system, Good Health and Well Being, Humans, COVID-19, Glycosylation, SARS-CoV-2, Glycosyltransferases, Complement System Proteins, Immunoglobulin M, IMPACC Network
Abstract

The glycosylation of IgG plays a critical role during human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during human acute viral infection. The analysis of IgM N-glycosylation from healthy controls and hospitalized coronavirus disease 2019 (COVID-19) patients reveals increased high-mannose and sialylation that correlates with COVID-19 severity. These trends are confirmed within SARS-CoV-2-specific immunoglobulin N-glycan profiles. Moreover, the degree of total IgM mannosylation and sialylation correlate significantly with markers of disease severity. We link the changes of IgM N-glycosylation with the expression of Golgi glycosyltransferases. Lastly, we observe antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients and modulated by exoglycosidase digestion. Taken together, this work links the IgM N-glycosylation with COVID-19 severity and highlights the need to understand IgM glycosylation and downstream immune function during human disease.

Published
2024

2. Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study

Author

Ozonoff, Al, Schaenman, Joanna, Jayavelu, Naresh Doni, Milliren, Carly E, Calfee, Carolyn S, Cairns, Charles B, Kraft, Monica, Baden, Lindsey R, Shaw, Albert C, Krammer, Florian, van Bakel, Harm, Esserman, Denise A, Liu, Shanshan, Sesma, Ana Fernandez, Simon, Viviana, Hafler, David A, Montgomery, Ruth R, Kleinstein, Steven H, Levy, Ofer, Bime, Christian, Haddad, Elias K, Erle, David J, Pulendran, Bali, Nadeau, Kari C, Davis, Mark M, Hough, Catherine L, Messer, William B, Higuita, Nelson I Agudelo, Metcalf, Jordan P, Atkinson, Mark A, Brakenridge, Scott C, Corry, David, Kheradmand, Farrah, Ehrlich, Lauren IR, Melamed, Esther, McComsey, Grace A, Sekaly, Rafick, Diray-Arce, Joann, Peters, Bjoern, Augustine, Alison D, Reed, Elaine F, Altman, Matthew C, Becker, Patrice M, Rouphael, Nadine, Bime, Chris, McEnaney, Kerry, Barton, Brenda, Lentucci, Claudia, Saluvan, Mehmet, Chang, Ana C, Hoch, Annmarie, Albert, Marisa, Shaheen, Tanzia, Kho, Alvin T, Thomas, Sanya, Chen, Jing, Murphy, Maimouna D, Cooney, Mitchell, Presnell, Scott, and Fragiadakis, Gabriela K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Coronaviruses, Lung, Emerging Infectious Diseases, Prevention, Genetics, Clinical Research, Good Health and Well Being, COVID-19, Creatinine, Female, Hospitalization, Humans, Male, Phenotype, Prospective Studies, RNA, Viral, SARS-CoV-2, Severity of Illness Index, Troponin, Post-Acute COVID-19 Syndrome, Viral load, Antibody, IMPACC study group members, Public Health and Health Services, Clinical sciences, Epidemiology
Abstract

BackgroundBetter understanding of the association between characteristics of patients hospitalized with coronavirus disease 2019 (COVID-19) and outcome is needed to further improve upon patient management.MethodsImmunophenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective, observational study of 1164 patients from 20 hospitals across the United States. Disease severity was assessed using a 7-point ordinal scale based on degree of respiratory illness. Patients were prospectively surveyed for 1 year after discharge for post-acute sequalae of COVID-19 (PASC) through quarterly surveys. Demographics, comorbidities, radiographic findings, clinical laboratory values, SARS-CoV-2 PCR and serology were captured over a 28-day period. Multivariable logistic regression was performed.FindingsThe median age was 59 years (interquartile range [IQR] 20); 711 (61%) were men; overall mortality was 14%, and 228 (20%) required invasive mechanical ventilation. Unsupervised clustering of ordinal score over time revealed distinct disease course trajectories. Risk factors associated with prolonged hospitalization or death by day 28 included age ≥ 65 years (odds ratio [OR], 2.01; 95% CI 1.28-3.17), Hispanic ethnicity (OR, 1.71; 95% CI 1.13-2.57), elevated baseline creatinine (OR 2.80; 95% CI 1.63- 4.80) or troponin (OR 1.89; 95% 1.03-3.47), baseline lymphopenia (OR 2.19; 95% CI 1.61-2.97), presence of infiltrate by chest imaging (OR 3.16; 95% CI 1.96-5.10), and high SARS-CoV2 viral load (OR 1.53; 95% CI 1.17-2.00). Fatal cases had the lowest ratio of SARS-CoV-2 antibody to viral load levels compared to other trajectories over time (p=0.001). 589 survivors (51%) completed at least one survey at follow-up with 305 (52%) having at least one symptom consistent with PASC, most commonly dyspnea (56% among symptomatic patients). Female sex was the only associated risk factor for PASC.InterpretationIntegration of PCR cycle threshold, and antibody values with demographics, comorbidities, and laboratory/radiographic findings identified risk factors for 28-day outcome severity, though only female sex was associated with PASC. Longitudinal clinical phenotyping offers important insights, and provides a framework for immunophenotyping for acute and long COVID-19.FundingNIH.

Published
2022

3. Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study

Author

Rouphael, Nadine, Maecker, Holden, Montgomery, Ruth R, Diray-Arce, Joann, Kleinstein, Steven H, Altman, Matthew C, Bosinger, Steven E, Eckalbar, Walter, Guan, Leying, Hough, Catherine L, Krammer, Florian, Langelier, Charles, Levy, Ofer, McEnaney, Kerry, Peters, Bjoern, Rahman, Adeeb, Rajan, Jayant V, Sigelman, Steven, Steen, Hanno, van Bakel, Harm, Ward, Alyssa, Wilson, Michael R, Woodruff, Prescott, Zamecnik, Colin R, Augustine, Alison D, Ozonoff, Al, Reed, Elaine F, Becker, Patrice M, Higuita, Nelson Agudelo, Atkinson, Mark A, Baden, Lindsey R, Bime, Christian, Brakenridge, Scott C, Calfee, Carolyn S, Cairns, Charles B, Corry, David, Davis, Mark M, Ehrlich, Lauren IR, Haddad, Elias K, Erle, David J, Fernandez-Sesma, Ana, Hafler, David A, Kheradmand, Farrah, Kraft, Monica, McComsey, Grace A, Melamed, Esther, Messer, William, Metcalf, Jordan, Nadeau, Kari C, Pulendran, Bali, Sarwal, Minnie, Schaenman, Joanna, Sekaly, Rafick, Shaw, Albert C, and Simon, Viviana

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Coronaviruses Therapeutics and Interventions, Clinical Research, Minority Health, Emerging Infectious Diseases, Coronaviruses, 2.4 Surveillance and distribution, 4.2 Evaluation of markers and technologies, 4.1 Discovery and preclinical testing of markers and technologies, Biomarkers, COVID-19, Computational Biology, Data Analysis, Gene Expression Profiling, Hospitalization, Humans, Immunophenotyping, Longitudinal Studies, Molecular Diagnostic Techniques, Prospective Studies, Proteomics, SARS-CoV-2, United States, IMPACC Manuscript Writing Team, IMPACC Network Steering Committee, Clinical sciences, Immunology
Abstract

The IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective longitudinal study designed to enroll 1000 hospitalized patients with COVID-19 (NCT04378777). IMPACC collects detailed clinical, laboratory and radiographic data along with longitudinal biologic sampling of blood and respiratory secretions for in depth testing. Clinical and lab data are integrated to identify immunologic, virologic, proteomic, metabolomic and genomic features of COVID-19-related susceptibility, severity and disease progression. The goals of IMPACC are to better understand the contributions of pathogen dynamics and host immune responses to the severity and course of COVID-19 and to generate hypotheses for identification of biomarkers and effective therapeutics, including optimal timing of such interventions. In this report we summarize the IMPACC study design and protocols including clinical criteria and recruitment, multi-site standardized sample collection and processing, virologic and immunologic assays, harmonization of assay protocols, high-level analyses and the data sharing plans.

Published
2021

4. Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients

Author

Diray-Arce, Joann, Fourati, Slim, Doni Jayavelu, Naresh, Patel, Ravi, Maguire, Cole, Chang, Ana C, Dandekar, Ravi, Qi, Jingjing, Lee, Brian H, van Zalm, Patrick, Schroeder, Andrew, Chen, Ernie, Konstorum, Anna, Brito, Anderson, Gygi, Jeremy P, Kho, Alvin, Chen, Jing, Pawar, Shrikant, Gonzalez-Reiche, Ana Silvia, Hoch, Annmarie, Milliren, Carly E, Overton, James A, Westendorf, Kerstin, IMPACC Network, Cairns, Charles B, Rouphael, Nadine, Bosinger, Steven E, Kim-Schulze, Seunghee, Krammer, Florian, Rosen, Lindsey, Grubaugh, Nathan D, van Bakel, Harm, Wilson, Michael, Rajan, Jayant, Steen, Hanno, Eckalbar, Walter, Cotsapas, Chris, Langelier, Charles R, Levy, Ofer, Altman, Matthew C, Maecker, Holden, Montgomery, Ruth R, Haddad, Elias K, Sekaly, Rafick P, Esserman, Denise, Ozonoff, Al, Becker, Patrice M, Augustine, Alison D, Guan, Leying, Peters, Bjoern, and Kleinstein, Steven H

Subjects
screening and diagnosis, IMPACC Network, SARS-CoV-2, longitudinal modeling, Prevention, COVID-19, systems immunology, multi-omics, Multiomics, 4.1 Discovery and preclinical testing of markers and technologies, Detection, Rare Diseases, Good Health and Well Being, immunophenotyping, Clinical Research, Disease Progression, Humans, 2.1 Biological and endogenous factors, Longitudinal Studies, Aetiology
Abstract

The IMPACC cohort, composed of >1,000 hospitalized COVID-19 participants, contains five illness trajectory groups (TGs) during acute infection (first 28days), ranging from milder (TG1-3) to more severe disease course (TG4) and death (TG5). Here, we report deep immunophenotyping, profiling of >15,000 longitudinal blood and nasal samples from 540 participants of the IMPACC cohort, using 14 distinct assays. These unbiased analyses identify cellular and molecular signatures present within 72h of hospital admission that distinguish moderate from severe and fatal COVID-19 disease. Importantly, cellular and molecular states also distinguish participants with more severe disease that recover or stabilize within 28days from those that progress to fatal outcomes (TG4 vs. TG5). Furthermore, our longitudinal design reveals that these biologic states display distinct temporal patterns associated with clinical outcomes. Characterizing host immune responses in relation to heterogeneity in disease course may inform clinical prognosis and opportunities for intervention.

Published
2023

5. Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study

Author

Rouphael, Nadine, Maecker, Holden, Montgomery, Ruth R., Diray-Arce, Joann, Kleinstein, Steven H., Altman, Matthew C., Bosinger, Steven E., Eckalbar, Walter, Guan, Leying, Hough, Catherine L., Krammer, Florian, Langelier, Charles, Levy, Ofer, McEnaney, Kerry, Peters, Bjoern, Rahman, Adeeb, Rajan, Jayant V., Sigelman, Steven, Steen, Hanno, van Bakel, Harm, Ward, Alyssa, Wilson, Michael R., Woodruff, Prescott, Zamecnik, Colin R., Augustine, Alison D., Ozonoff, Al, Reed, Elaine F., Becker, Patrice M., Higuita, Nelson Agudelo, Atkinson, Mark A., Baden, Lindsey R., Bime, Christian, Brakenridge, Scott C., Calfee, Carolyn S., Cairns, Charles B., Corry, David, Davis, Mark M., Ehrlich, Lauren I. R., Haddad, Elias K., Erle, David J., Fernandez-Sesma, Ana, Hafler, David A., Kheradmand, Farrah, Kraft, Monica, McComsey, Grace A., Melamed, Esther, Messer, William, Metcalf, Jordan, Nadeau, Kari C., Pulendran, Bali, Sarwal, Minnie, Schaenman, Joanna, Sekaly, Rafick, Shaw, Albert C., and Simon, Viviana

Subjects
Oncology, Data Analysis, Proteomics, medicine.medical_specialty, Longitudinal study, Immunology, Psychological intervention, MEDLINE, Immunophenotyping, Clinical Research, Internal medicine, Research Resources, medicine, Research Resource, Humans, Sampling (medicine), Longitudinal Studies, Prospective Studies, Prospective cohort study, SciImmunol r-resources, business.industry, SARS-CoV-2, Systems Biology, Gene Expression Profiling, COVID-19, Computational Biology, General Medicine, United States, Coronavirus, Hospitalization, Molecular Diagnostic Techniques, Cohort, Sample collection, business, Biomarkers
Abstract

Description, IMPACC is a multicenter longitudinal study assessing clinical and immunologic manifestations of COVID-19 in hospitalized patients., The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective longitudinal study designed to enroll 1000 hospitalized patients with COVID-19 (NCT04378777). IMPACC collects detailed clinical, laboratory, and radiographic data along with longitudinal biologic sampling of blood and respiratory secretions for in-depth testing. Clinical and laboratory data are integrated to identify immunologic, virologic, proteomic, metabolomic, and genomic features of COVID-19–related susceptibility, severity, and disease progression. The goals of IMPACC are to better understand the contributions of pathogen dynamics and host immune responses to the severity and course of COVID-19 and to generate hypotheses for identification of biomarkers and effective therapeutics, including optimal timing of such interventions. In this report, we summarize the IMPACC study design and protocols including clinical criteria and recruitment, multisite standardized sample collection and processing, virologic and immunologic assays, harmonization of assay protocols, high-level analyses, and the data sharing plans.

Catalog

Books, media, physical & digital resources
See catalog results